Panel Backs Bone Drugs for Postmenopausal Breast Cancer

Excerpt:

“Appropriately selected postmenopausal women with breast cancer warrant consideration for adjuvant bisphosphonate therapy, according to an updated clinical guideline.

“Either zoledronic acid (Zometa) or clodronate may be considered for adjuvant therapy, as data supporting use of other bisphosphonates remain limited. The RANK ligand-targeted monoclonal antibody denosumab (Xgeva) did not make the cut as recommended therapy because of a lack of long-term survival data to support its use.

” ‘Data for adjuvant denosumab look promising but are currently insufficient to make any recommendation,’ concluded a panel of experts representing the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.


Bone Drugs Equal as Breast Cancer Therapies

“One bone-preserving drug is as good as another in early stage breast cancer, a researcher said here.

“In a large randomized trial, there were few differences in anti-cancer efficacy among three different members of the bisphosphonate class, according to Julie Gralow, MD, of the University of Washington in Seattle.

“And the overall safety of the drugs was also similar, Gralow reported at the annual meeting of the American Society of Clinical Oncology.

“But the study might not help settle a continuing controversy in oncology over the use of the drugs, which normally are prescribed to slow bone embrittlement by inhibiting the action of osteoclasts.”